FEIBA versus plasma for bleeding after heart surgery
Part of Heart & circulation clinical trials.
This trial compares two treatments for bleeding after heart surgery: a medicine called FEIBA (which helps blood clot) and fresh frozen plasma (a blood product). The goal is to see which works better as a first treatment for bleeding during recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are scheduled for non-emergency heart surgery (not bypass) that uses a heart-lung machine
- You have bleeding that needs a factor transfusion
- You do not have a history of allergic reaction to FEIBA or blood products
- You are not pregnant and do not have blood clotting disorders like DIC or HIT
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood thinner in people with new, temporary atrial fibrillation after CABG (heart bypass surgery) can reduce harmful outcomes compared with standard treatment. It may help prevent stroke or other complications if your rhythm problem fits the trial’s timing and risk profile.
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
This trial compares two treatments (prothrombin complex concentrate and fresh frozen plasma) for managing bleeding during heart surgery. It aims to find which approach works better and is safer for patients.
This trial tests whether giving a personalized dose of fibrinogen, a protein that helps blood clot, after heart surgery reduces bleeding and the need for blood transfusions. It aims to improve recovery for patients who need fibrinogen after being on a heart-lung machine.
This study looks back at patient records from heart surgeries that used a heart-lung machine to see how the availability of a medicine called fibrinogen affected blood transfusions and recovery. It helps us understand if wider access to this treatment improves outcomes.
This trial is for hospitals, not patients. Hospitals that do many open heart surgeries and whose doctors agree to use certain bleeding control drugs (fibrinolysis inhibitors) as per the study protocol can participate.
Hear when a new Cardiac Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.